Tissue (µg eq/g) n=3

Oral (time after first dose) 6

Transdermal (time after application)

168h

192h

216h

312h

504h

168h

192h

216h

312h

504h

Blood/Plasma

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

Adrenal Gland

0.47

0.42

0.15

0.26

LOQ

1.75

1.54

LOQ

LOQ

0.61

Aorta

0.65

0.20

LOQ

0.22

LOQ

LOQ

LOQ

LOQ

13.74

LOQ

Eye

163.40

157.21

172.44

112.49

92.14

76.23

118.61

67.65

42.56

21.49

Liver

1.30

0.36

0.11

LOQ

LOQ

1.98

2.08

0.60

LOQ

LOQ

Pituitary

LOQ

1.96

LOQ

0.86

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

Stomach

0.28

LOQ

LOQ

LOQ

LOQ

0.25

0.15

LOQ

LOQ

LOQ

Small Intestine

0.86

LOQ

LOQ

LOQ

LOQ

1.10

0.66

0.14

LOQ

LOQ

Large Intestine

1.32

LOQ

LOQ

LOQ

LOQ

0.87

0.75

0.16

LOQ

LOQ

Skin-Pigmented

11.44

25.68

31.05

9.64

8.32

14.87

7.76

4.51

4.36

2.76

Skin-Unpigmented

0.52

LOQ

LOQ

LOQ

0.75

0.39

0.58

LOQ

LOQ

LOQ

Thyroid/Parathyroid

LOQ

0.64

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

LOQ

Dose Site

Pigmented

NA

72.04

8.69

23.77

8.49

LOQ

Unpigmented

NA

88.91

8.37

10.31

4.99

1.86

Stratum Corneum7

NA

12.70

2.92

2.49

0.65

0.49

LOQ = below limit of quantitation; NA = not applicable to route of administration
6 Days 1 and 2 – 30 mg/kg; days 3-7, 10 mg/kg; oral gavage
7 Expressed as per cent of dose (mean dose of 42.4 mg/kg)
Table 2b: Mean Radioactivity in Blood, Plasma, Selected Tissues and Stratum Corneum (Transdermal only) from Long-Evans Rats Administered a Repeated Oral
14C-Donepezil or 7-Day Transdermal Patch Containing 14C-Donepezil.